Psychopharmacology - Module 1: Overview of Childhood Disorders

For professionals seeking background on childhood medication discussions, this multidisciplinary recording examines medication categories, target symptoms, assessment, monitoring and family concerns alongside behavioral and educational care. The catalogue credits Ronald T. Brown, Deborah P. Coehlo and Lyre C. Fribourg.

Catalogue presenter credits: Ronald T. Brown, Deborah P. Coehlo, Lyre C. Fribourg.

Certificate of Completion. This session does not offer BACB continuing education (CE) credit.

MANDATORY DISCLAIMER: The Behavior Analyst Certification Board  (“BACB”) does not sponsor, approve or endorse Special Learning, the materials, information, or sessions identified herein.

The panel surveys antidepressants, anxiety and obsessive-compulsive disorder, ADHD medication families and mood-related medications. It also explains pharmacokinetics, pharmacodynamics and half-life as part of the recorded overview.

The discussion follows information across home, school and healthcare settings and considers family beliefs and barriers to taking prescribed medication. Detailed case studies are deferred to later modules, and the session does not provide a worked medication-change tracking log.

What does this recording cover?

• Internalizing, externalizing and neurodevelopmental groupings organize the discussion of medication classes and target symptoms.
• The panel introduces antidepressant, ADHD and mood-related medication categories.
• Pharmacokinetics, pharmacodynamics and half-life frame the explanation of medication movement and response.
• Assessment and monitoring draw on reports from children, families, teachers and other settings.
• Family concerns, dosing inconvenience and pill-swallowing difficulties feature in the discussion of adherence.

Recording context: The recording date is not supplied. Research, professional requirements and examples reflect the discussion at the time of delivery.

Three selected learner comments

The six-item evaluation mean was 3.95/5 across 26 complete responses, from 119 recorded rating responses. This mean includes only complete six-score responses. Source: Special Learning's course evaluation records, snapshot October 11, 2026.

Three selected anonymous responses appear below, with the wording and spelling retained. They describe learners' experiences and requests; they are not a guarantee of results or a claim that these comments represent every learner.

It was very informative and engaging.

Course evaluation response, 2024

N/A. The webinar was great and useful for my practice.

Course evaluation response, 2024

Include some case studies

Course evaluation response, 2024

Explore related recorded discussions

• Psychopharmacology - Module 4: PsyPharm & Mood Disorders
• ADHD and Medication: What the Evidence Says
• View this course's purchase and access details